Most cited papers from Lublin Oncology Center

Lublin Oncology Center

What are the most cited papers from Lublin Oncology Center?

The most cited paper from Lublin Oncology Center is "Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma" (Gary R. Hudes, Michael Anthony Carducci, Piotr Tomczak et al., 2007), with 3,671 citations. Next come "Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review" (1,968) and "Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies" (1,601).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 80 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma Gary R. Hudes, Michael Anthony Carducci, Piotr Tomczak et al. · New England Journal of Medicine	30 May 2007	3,671
2	Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma et al. · Cancers Open access	25 Aug 2021	1,968
3	Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies Julita Machlowska, Jacek Baj, Monika Sitarz et al. · International Journal of Molecular Sciences Open access	4 Jun 2020	1,601
4	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Luca Gianni et al. · The Lancet Oncology	26 Feb 2011	614
5	The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial M. M. Heiss, P. Murawa, P. Koralewski et al. · International Journal of Cancer Open access	28 Apr 2010	557
6	Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study Krzysztof Bujko et al. · Annals of Oncology Open access115 authors	16 Feb 2016	448
7	Ribociclib plus Endocrine Therapy in Early Breast Cancer Dennis J. Slamon et al. · New England Journal of Medicine	20 Mar 2024	395
8	Breast cancer risk factors Marzena Kamińska, Tomasz Ciszewski, Karolina Łopacka-Szatan et al. · Menopause Review/Przegląd Menopauzalny Open access	2015	379
9	Primary and secondary prevention of breast cancer Agnieszka Kolak, Marzena Kamińska, Katarzyna Sygit et al. · Annals of Agricultural and Environmental Medicine Open access	18 Jul 2017	350
10	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients Tomasz Byrski, Tomasz Huzarski, Rebecca Alexandra Dent et al. · Breast Cancer Research and Treatment Open access	22 Jul 2008	341
11	Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study Bogumiła Ciseł et al. · Annals of Oncology Open access	6 Jun 2019	324
12	SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer Luis Chiva et al. · International Journal of Gynecological Cancer Open access147 authors	12 Aug 2020	307
13	Quality of life of patients with lung cancer Mariusz Chabowski, Jacek Polański, Beata Jankowska‐Polańska et al. · OncoTargets and Therapy Open access	Feb 2016	299
14	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling Dongjun Peng et al. · Cancer Research Open access	7 Apr 2016	278
15	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients Tomasz Byrski, Tomasz Huzarski, R. A. Dent et al. · Breast Cancer Research and Treatment	16 Aug 2014	271
16	Physical and psychological impairments of women with upper limb lymphedema following breast cancer treatment Angelika Chachaj, Krzysztof Małyszczak, Krystian Pyszel et al. · Psycho-Oncology Open access	27 Apr 2009	247
17	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study Burt Nabors, Karen E. Fink, Tom Mikkelsen et al. · Neuro-Oncology Open access	11 Mar 2015	240
18	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial John Robert Mackey et al. · The Lancet Oncology	11 Dec 2012	225
19	Genetic Markers in Lung Cancer Diagnosis: A Review Katarzyna Wadowska, Iwona Bil‐Lula, Łukasz Trembecki et al. · International Journal of Molecular Sciences Open access	27 Jun 2020	222
20	Ketogenic diet guidelines for infants with refractory epilepsy Elles J. T. M. van der Louw, Dorine van den Hurk, Elizabeth G. Neal et al. · European Journal of Paediatric Neurology Open access	18 Jul 2016	213
21	A high proportion of founder BRCA1 mutations in Polish breast cancer families Bohdan Górski et al. · International Journal of Cancer Open access	15 Mar 2004	196
22	Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis Cezary Cybulski, Wojciech Kluźniak, Tomasz Huzarski et al. · The Lancet Oncology	7 May 2015	167
23	Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers Tomasz Byrski, Jacek Gronwald, Tomasz Huzarski et al. · Breast Cancer Research and Treatment	9 May 2007	139
24	Marjolin’s ulcer in chronic wounds – review of available literature Dariusz Bazaliński, Joanna Zofia Przybek-Mita, Beata Barańska et al. · Współczesna Onkologia Open access	2017	138
25	Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial Saad Z. Usmani et al. · Nature Medicine Open access	5 Feb 2025	136
26	Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma Ursula A. Matulonis, Sudarshan Kumar Sharma, Sharad Ghamande et al. · Gynecologic Oncology	6 Jul 2012	135
27	Palmatine: A review of pharmacological properties and pharmacokinetics Dominik Tarabasz, Wirginia Kukuła‐Koch · Phytotherapy Research	8 Sep 2019	133
28	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis Renata Duchnowska, Rafał Pęksa, Barbara S. Radecka et al. · Breast Cancer Research Open access	26 Apr 2016	133
29	Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer Gabriele Minuti, Federico Cappuzzo, Renata Duchnowska et al. · British Journal of Cancer Open access	31 Jul 2012	128
30	Breast cancer predisposing alleles in Poland Bohdan Górski et al. · Breast Cancer Research and Treatment	27 Jun 2005	127
31	Cytogenetics of Synovial Sarcoma: Presentation of Ten New Cases and Review of the Literature Janusz Limon, Krzysztof Mrózek, N. Mandant et al. · Genes Chromosomes and Cancer	Sep 1991	126
32	Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma Anna Torres, Kamil Torres, Anna Pesci et al. · BMC Cancer Open access	24 Aug 2012	123
33	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy Ahmad Hussein Awada, Luc Yves Dirix, L. Manso Sanchez et al. · Annals of Oncology Open access	12 Sep 2012	117
34	Increased percentage of Th17 cells in peritoneal fluid is associated with severity of endometriosis Marek Gogacz, Izabela Winkler, Agnieszka Bojarska−Junak et al. · Journal of Reproductive Immunology	21 May 2016	116
35	Anticancer, antioxidant, and antibacterial activities of low molecular weight bioactive subfractions isolated from cultures of wood degrading fungus Cerrena unicolor Anna Matuszewska, Magdalena Jaszek, Dawid Stefaniuk et al. · PLoS ONE Open access	6 Jun 2018	115
36	GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance Oliver J. Ott et al. · Radiotherapy and Oncology	Jul 2016	112
37	A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) Lori J. Goldstein et al. · Breast Cancer Research and Treatment Open access	3 Sep 2021	107
38	Breast cancer metastasis – insight into selected molecular mechanisms of the phenomenon Jarosław Kozłowski, Aleksandra Kozłowska, Janusz Kocki · Postępy Higieny i Medycyny Doświadczalnej Open access	8 Apr 2015	104
39	Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain Renata Duchnowska, Rafał Dziadziuszko, Tomasz Trojanowski et al. · Breast Cancer Research Open access	16 Aug 2012	104
40	Esters of betulin and betulinic acid with amino acids have improved water solubility and are selectively cytotoxic toward cancer cells Małgorzata Drąg‐Zalesińska, Julita Kulbacka, Jolanta Saczko et al. · Bioorganic & Medicinal Chemistry Letters	15 Jun 2009	102
41	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Paul Gerard Guy Richardson et al. · Journal of Clinical Oncology Open access	11 Jun 2021	101
42	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ Patrick Schöffski et al. · Annals of Oncology Open access	15 Sep 2017	101
43	Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma Bartosz Puła, Aleksandra Jethon, Aleksandra Piotrowska et al. · Histopathology	Dec 2011	101
44	Robotic-Assisted vs. Standard Laparoscopic Surgery for Rectal Cancer Resection: A Systematic Review and Meta-Analysis of 19,731 Patients Kamil Safiejko, Radosław Tarkowski, Maciej Koselak et al. · Cancers ReviewOpen access	30 Dec 2021	100
45	Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer Nicholas J. Vogelzang et al. · JAMA Oncology Open access183 authors	10 Feb 2022	99
46	Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial. Implication for subsequent local excision Krzysztof Bujko, Marek P. Nowacki, Anna Maria Nasierowska-Guttmejer et al. · Radiotherapy and Oncology	27 May 2005	97
47	Prognostic Evaluation of Proliferative Activity and DNA Content in the Phyllodes Tumor of the Breast: Immunohistochemical and Flow Cytometric Study of 118 Cases Aleksander Niezabitowski, Bożena Lackowska, Janusz Ryś et al. · Breast Cancer Research and Treatment	2001	97
48	Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients Renata Duchnowska, Jacek Jassem, Chirayu Pankaj Goswami et al. · Journal of Neuro-Oncology Open access	5 Jan 2015	91
49	Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases? Violetta Opoka‐Winiarska, Ewelina Grywalska, Jacek Roliński · BMC Medicine Open access	15 Jul 2020	90
50	Comparision of the Cytotoxic Effects of Birch Bark Extract, Betulin and Betulinic Acid Towards Human Gastric Carcinoma and Pancreatic Carcinoma Drug-sensitive and Drug-Resistant Cell Lines Marcin Drąg, Paweł Surowiak, Małgorzata Drąg‐Zalesińska et al. · Molecules Open access	24 Apr 2009	90

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.